drugset / Trial / NCT03386838
An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a study of Nivolumab in combination with experimental medication BMS-986205 compared to the standard of care EXTREME regimen in head and neck cancer that has come back after initial treatment, or is widespread when first diagnosed.
Timeline
- Start
- 2018-03-28
- Primary completion
- 2018-04-19
- Completion
- 2018-04-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Carboplatin | Small molecule | 5 unknown | — |
| Comparator | Cetuximab | Monoclonal antibody | 250 mg/m2 | Intravenous |
| Comparator | Cisplatin | Other / unclassified | 100 mg/m2 | — |
| Subject | LINRODOSTAT | Small molecule | 100 mg | Oral |
| Subject | Nivolumab | Monoclonal antibody | — | — |
| Comparator | fluorouracil | Small molecule | 1000 mg/m2 | — |